All Outputs (10)

Assessment of HMGA2 and PLAG1 rearrangements in breast adenomyoepitheliomas (2019)
Journal Article
Pareja, F., Geyer, F. C., Brown, D. N., Sebastião, A. P. M., Gularte-Mérida, R., Li, A., …Reis-Filho, J. S. (2019). Assessment of HMGA2 and PLAG1 rearrangements in breast adenomyoepitheliomas. npj Breast Cancer, 5, Article 6 (2019). https://doi.org/10.1038/s41523-018-0101-7

Breast adenomyoepitheliomas (AMEs) are rare epithelial-myoepithelial neoplasms that may occasionally produce myxochondroid matrix, akin to pleomorphic adenomas (PAs). Regardless of their anatomic location, PAs often harbor rearrangements involving HM... Read More about Assessment of HMGA2 and PLAG1 rearrangements in breast adenomyoepitheliomas.

Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline focused update (2018)
Journal Article
Wolff, A. C., Hammond, M. E. H., Allison, K. H., Harvey, B. E., Mangu, P. B., Bartlett, J. M., …Dowsett, M. (2018). Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline focused update. Archives of Pathology and Laboratory Medicine, 142(11), 1364-1382. https://doi.org/10.5858/arpa.2018-0902-sa

© 2018 College of American Pathologists Published by the College of American Pathologists Allen Press, Inc. Purpose. - To update key recommendations of the American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) human epid... Read More about Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline focused update.

Correction to: Heregulin ?1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells (2018)
Journal Article
Hutcheson, I. R., Knowlden, J. M., Hiscox, S. E., Barrow, D., Gee, J. M. W., Robertson, J. F., …Nicholson, R. I. (2018). Correction to: Heregulin β1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells. Breast Cancer Research, 20, Article 98 (2018). https://doi.org/10.1186/s13058-018-0999-6

© 2018 The Author(s). After the publication of this work [1], an error was noticed in Fig. 2b and Fig. 4b as well as Fig. 4b. and Fig. 5d. Images of the ERK1/2 blots were accidentally duplicated. In Fig. 5a. and Fig. 5c., the last lane for p-ERK1/2 w... Read More about Correction to: Heregulin ?1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells.

Loss-of-function mutations in ATP6AP1 and ATP6AP2 in granular cell tumors (2018)
Journal Article
Pareja, F., Brandes, A. H., Basili, T., Selenica, P., Geyer, F. C., Fan, D., …Reis-Filho, J. S. (2018). Loss-of-function mutations in ATP6AP1 and ATP6AP2 in granular cell tumors. Nature Communications, 9, Article 3533. https://doi.org/10.1038/s41467-018-05886-y

Granular cell tumors (GCTs) are rare tumors that can arise in multiple anatomical locations, and are characterized by abundant intracytoplasmic granules. The genetic drivers of GCTs are currently unknown. Here, we apply whole-exome sequencing and tar... Read More about Loss-of-function mutations in ATP6AP1 and ATP6AP2 in granular cell tumors.

Diagnostic concordance of reporting lymphovascular invasion in breast cancer (2018)
Journal Article
Rakha, E. A., Abbas, A., Pinto Ahumada, P., ElSayed, M. E., Colman, D., Pinder, S. E., & Ellis, I. O. (2018). Diagnostic concordance of reporting lymphovascular invasion in breast cancer. Journal of Clinical Pathology, 71(9), (802-805). doi:10.1136/jclinpath-2017-204981. ISSN 0021-9746

Aims: This study aims to assess the diagnostic agreement of lymphovascular invasion (LVI) in invasive breast cancer (BC). Methods: Data on LVI were collected from the UK National Health Service Breast Screening Programme pathology external quality... Read More about Diagnostic concordance of reporting lymphovascular invasion in breast cancer.

Associations between genomic stratification of breast cancer and centrally reviewed tumour pathology in the METABRIC cohort (2018)
Journal Article
Mukherjee, A., Russell, R., Chin, S., Liu, B., Rueda, O., Ali, H., …Provenzano, E. (2018). Associations between genomic stratification of breast cancer and centrally reviewed tumour pathology in the METABRIC cohort. npj Breast Cancer, 4(1), Article 5. https://doi.org/10.1038/s41523-018-0056-8

The integration of genomic and transcriptomic profiles of 2000 breast tumours from the METABRIC [Molecular Taxonomy of Breast Cancer International Consortium] cohort revealed ten subtypes, termed integrative clusters (IntClust/s), characterised by di... Read More about Associations between genomic stratification of breast cancer and centrally reviewed tumour pathology in the METABRIC cohort.

The localization of pre mRNA splicing factor PRPF38B is a novel prognostic biomarker that may predict survival benefit of trastuzumab in patients with breast cancer overexpressing HER2 (2017)
Journal Article
Abdel-Fatah, T. M., Rees, R. C., Pockley, A. G., Moseley, P., Ball, G. R., Chan, S. Y., …Miles, A. K. (2017). The localization of pre mRNA splicing factor PRPF38B is a novel prognostic biomarker that may predict survival benefit of trastuzumab in patients with breast cancer overexpressing HER2. Oncotarget, 8(68), 112245-112257. https://doi.org/10.18632/oncotarget.22496

Cancer biomarkers that can define disease status and provide a prognostic insight are essential for the effective management of patients with breast cancer (BC). The prevalence, clinicopathological and prognostic significance of PRPF38B expression... Read More about The localization of pre mRNA splicing factor PRPF38B is a novel prognostic biomarker that may predict survival benefit of trastuzumab in patients with breast cancer overexpressing HER2.

Genetic events in the progression of adenoid cystic carcinoma of the breast to high-grade triple-negative breast cancer (2016)
Journal Article
Fusco, N., Geyer, F. C., De Filippo, M. R., Martelotto, L. G., Ng, C. K., Piscuoglio, S., …Weigelt, B. (2016). Genetic events in the progression of adenoid cystic carcinoma of the breast to high-grade triple-negative breast cancer. Modern Pathology, 29(11), 1292-1305. https://doi.org/10.1038/modpathol.2016.134

Adenoid cystic carcinoma of the breast is a rare histological type of triple-negative breast cancer with an indolent clinical behavior, often driven by the MYB-NFIB fusion gene. Here we sought to define the repertoire of somatic genetic alterations i... Read More about Genetic events in the progression of adenoid cystic carcinoma of the breast to high-grade triple-negative breast cancer.

Review of the national external quality assessment (EQA) scheme for breast pathology in the UK (2016)
Journal Article
Rakha, E. A., Bennett, R. L., Coleman, D., Pinder, S. E., & Ellis, I. O. (2017). Review of the national external quality assessment (EQA) scheme for breast pathology in the UK. Journal of Clinical Pathology, 70(1), 51-57. doi:10.1136/jclinpath-2016-203800

Background: The National Health Service Breast Screening Programme (NHSBSP; pathology) external quality assurance (EQA) scheme aims to provide a mechanism for examination and monitoring of concordance of pathology reporting within the UK. This study... Read More about Review of the national external quality assessment (EQA) scheme for breast pathology in the UK.

Genomic and protein expression analysis reveals flap endonuclease 1 (FEN1) as a key biomarker in breast and ovarian cancer (2014)
Journal Article
Abdel-Fatah, T. M., Russell, R., Albarakati, N., Maloney, D. J., Dorjsuren, D., Rueda, O. M., …Madhusudan, S. (2014). Genomic and protein expression analysis reveals flap endonuclease 1 (FEN1) as a key biomarker in breast and ovarian cancer. Molecular Oncology, 8(7), 1326-1338. https://doi.org/10.1016/j.molonc.2014.04.009

FEN1 has key roles in Okazaki fragment maturation during replication, long patch base excision repair, rescue of stalled replication forks, maintenance of telomere stability and apoptosis. FEN1 may be dysregulated in breast and ovarian cancers and ha... Read More about Genomic and protein expression analysis reveals flap endonuclease 1 (FEN1) as a key biomarker in breast and ovarian cancer.